Topic Archives: HIV

Cyto Who?

[Ed. Note: Dr. KSS is an MD and PhD who writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see his past articles and recent comments here.] You’re probably getting it right by now—writing “2016” and not “2015.” […]

Comments

  • Avatar

    The ONLY gene editing stock to own is SGMO. No off targets unlike the rest. 7 readouts this year. Imo, will cure HIV ...

  • Avatar

    Outstanding review. Another interesting potential therapy involves the CCR5 receptor on T-cells. This receptor function...

  • Avatar

    Interesting article yet again Doc. The in-depth look into treatment progress for Lymes, HIV and Cancer was very insig...

  • Avatar

    $CYDY long - it's coming - I thought I was way overweight, but now wish I had more! CytoDyn to Present Primary Efficacy...

  • Gr8Full!

    New Infographic: The 10 Most #Innovative #HIV #Treatments to Defeat #AIDS. @ABIVAX_ @ViiVHC @Immunocore https://goo.gl...

  • Avatar

    $$CYDY VANCOUVER, Washington, Feb. 20, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) reports the successful achiev...

  • Gr8Full!

    $CYDY - CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection https:/...

  • Avatar

    Looking more and more like a lot of pump and dump activity was going on with the "inner circle" making off with nice gai...

  • Dr. KSS MD PhD

    BTX's Renevia technology is scaffold for injected cells that itself is gradually resorbed but only after implanted cell ...

  • Avatar

    $AUPH $ABBV $GILD $AMGN Dr. KSS, Thank you for your reply. The periodic dosing and potential for reintroduction...

  • Avatar

    I 'd say Hepatitis C, as it is a chronic form of hepatitis and has a high prevalence in specific groups of people that I...

  • Avatar

    Sambucol or elderberry extract is thought to have a mild affect on cancer, HIV and herpes. It is primarily used for flu...

  • SoGiAm

    $AAVXF Now long 1/3 position. #ThankYOU! #ZKSS! Been scouring the web for the data, to no avail. Have you found it?...

  • SoGiAm

    ABIVAX Announces Its Financial Calendar for 2018 PRESS RELEASE Businesswire Dec. 15, 2017, 12:00 PM Follow us on Twitt...

  • SoGiAm

    8th International Workshop on HIV Persistence during Therapy (HIV Persistence 2017) Conference Dates 12 - 15 Dec 2017 ...

  • SoGiAm

    ABIVAX’s ABX464 Phase IIa Data confirm HIV Reservoir Reduction in Oral Presentation at 8th International Workshop on H...

  • Avatar

    $ABVX.PA $AAVXF ABIVAX’s ABX464 Phase IIa Data confirm HIV Reservoir Reduction in Oral Presentation at 8th Internat...

  • Dr. KSS MD PhD

    Shredlee: the issue seems to be that Abivax can lower the reservoir burden but not eliminate it. If you will recall, tha...

  • Avatar

    $AAVXF $ABVX More on the Opdivo (nivolumab) effect. "those results suggest that nivolumab in this patient had induced...

  • Avatar

    Danmcco, same problem applies in countries like this that have high HIV rates. Thugs and thieves produce fake HIV drugs...

  • Avatar

    $GSK $HIV U.S. FDA approves first two-drug HIV regimen in victory for GSK Juluca® (dolutegravir and rilpivirine) ...

  • Dr. KSS MD PhD

    Wow, the top two are shockers, especially $AMGN. Who knew? We think of JNJ as venerated and wealthy and extremely well-p...

  • SoGiAm

    $AUPH #MF - So nice to read a good, succinct article vs https://www.statnews.com/2017/09/28/brigham-and-womens-hospita...

  • SoGiAm

    It's Friday the 13th... Beauoooo.... Have an awesome day #Gr8Gummune! https://twitter.com/BirdBrayn/status/918770505...

  • SoGiAm

    $CAPR long - Have a #hunch this is NOT the last time we #HEAR from Linda today!... WhatDoYouThink? Gilead announces ...

  • Avatar

    $ABVX long Abivax ABX464 reduces HIV reservoir in blood in second phase 2a trial. First ever drug candidate to show sta...

  • Avatar

    New antibody attacks 99% of HIV strains Just in from the BBC ........ http://www.bbc.com/news/health-41351159...

  • Avatar

    $AAVXF FIRST PATIENT DOSED IN THREE-MONTH COHORT OF PHASE 2A STUDY OF ORAL ABX464 IN HIV-SUPPRESSED PATIENTS Jean-Mar...

  • SoGiAm

    ABIVAX to present FULL ABX464 POSITIVE PHASE 2A CLINICAL HIV DATA AT THE HIV CURE AND RESERVOIR SYMPOSIUM. This will ta...

  • Avatar

    ABIVAX to present FULL ABX464 POSITIVE PHASE 2A CLINICAL HIV DATA AT THE HIV CURE AND RESERVOIR SYMPOSIUM. This will ta...

  • Avatar

    $ARGS Press Release yesterday, September 6, 2017 Argos Announces First Dosing of HIV Patient with AGS-004 Derived fro...

  • SoGiAm

    $CYDY - CytoDyn Provides Further Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV http://ir.cyto...

  • SoGiAm

    $CYDY long - CytoDyn Provides Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV VANCOUVER, Was...

  • SoGiAm

    Novel stem cell-derived model created of inflammatory neurological disorder Brain-in-a-dish approach also showed two ex...

  • Dr. KSS MD PhD

    Phil: You may already know it, but the study is gamed thus: the number of participants was chosen to have 90 percent pow...

  • SoGiAm

    #CYDY long - CytoDyn Provides Update on Enrollment in its Pivotal Phase 2b/3 HIV Combination Trial http://ir.cytodyn.com...

  • Avatar

    i tried to post these questions earlier but my internet failed me[i think] two questions for the community: 1] i just no...

  • Avatar

    $ABVX - competition or complement? Vorinostat renders dormant HIV infection vulnerable to clearance. https://www.scien...

  • Dr. KSS MD PhD

    Oh, about Abi. Remember a phase 1b-ish pharmacodynamic study involving giving 464 to patients and then assessing by rect...

  • SoGiAm

    $JNJ np - New #HIV and #HBV vaccine agreement expands collaboration with Janssen @JanssenGlobal http://www.bavarian-nord...

  • Avatar

    There is some J&J news re expansion of agreement with Bavarian Nordic re: HIV and Hep B vaccine area which may be th...

  • Avatar

    Abivax is chasing HIV not HCV...

  • Avatar

    $GILD Long I have a confession that I have been building up a $GILD position over the past month. If anyone cares wh...

  • Avatar

    $ABVX FP Gummie calender updates based on PR: "Based on the results of the ABX464-004 study, ABIVAX has submitted a pr...

  • Avatar

    $ABVX FP ABIVAX to present latest clinical data on ABX464 at the International Aids Society Conference in Paris, Franc...

  • Avatar

    Long $AAVXF. Great Nature article just published on IBD anti-inflammatory effect from ABX464. ABX464 has blockbuster...

  • Avatar

    $SCYX np -- Interesting rundown on the rise of fungal infections worldwide: ensia.com/features/19036/ Some excerpts: ...

  • Avatar

    $ABVX Long sp Abivax to present poster on July 24 at IAS2017. Title: "ABX464 decreases total HIV DNA in PBMC´s when ad...

  • Avatar

    $VBLT. Thanks, Doc. To be clear about this, I'm not questioning your medical knowledge or investment advice, both of...

  • Dr. KSS MD PhD

    That datum is disappointing, but what matters is diminution in PBMC HIV DNA, which has not been seen with another agent....

  • Avatar

    Thanks for the detailed response. I have observed over the last 20 years companies that try to treat HIV through monoclo...

  • Dr. KSS MD PhD

    Your link won't open. However, in general monoclonal antibodies have failed against the major RNA viruses HIV and HCV wh...

  • Avatar

    $Bioclonetics. Dr. KSS I would be interested in getting your take on this private company that is seeking to treat HIV u...

  • Avatar

    Trading update, long winded! Sold all of my remaining half position in $CYDY for a solid loss. Why? Latest corporate up...

  • Avatar

    I 'm trying to look harder for catalysts for ABVX, as I imagine quite a few of us have quite a bit of money in it! I ...

  • Avatar

    It may be the muslims carrying out attacks, like the bacterial invasion that kills an AIDS patient, but it is the HIV vi...

  • Avatar

    $CYDY abstract Abstract Title: Interim Results of PRO 140 in a Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients...

  • Dr. KSS MD PhD

    This is a massive public health problem now in the US, and a co-driver is the mess we've made in Afghanistan.....now her...

  • Dr. KSS MD PhD

    Curt: you raise a cluster of interesting and relevant issues. It does need to be pointed out that one can be on ART and ...

  • Avatar

    Re AAVXF: Some thoughts about HIV and Abivax's study subject pool have been troubling me, perhaps unnecessarily. I'm com...

  • Dr. KSS MD PhD

    They ARE going to do this in a French way. We will sell no wine before it's time, though I know Orson Welles said that. ...

  • Avatar

    Short EP Vantage interview with Jean-Marc Steens, Abivax’s chief medical officer: 'Abivax not getting ahead of itse...

  • Avatar

    $ABVX Has anyone commented on this alternative explanation for the ABIVAX HIV viral reservoir effect: "The explana...

  • Dr. KSS MD PhD

    Hi mettler: I tried to prise from them in what journal, but they wouldn't let on. Francophone vs Anglophone here: were i...

  • Dr. KSS MD PhD

    Yes, I'd not seen the video...it apparently was released today, no?---but had already alluded to it in a draft of a colu...

  • Avatar

    I too am interested in the ABX 464 IBD study and wonder if the impact on this and other inflammatory diseases holds even...

  • achandra13

    $ABVX Functional cure for HIV Dr. KSS have you seen this video? It talks about a vaccine and how along with another d...

  • Dr. KSS MD PhD

    Redsox/Peter: To continue musing about Abivax, let me make what I think is an important point. In the early days of t...

  • Dr. KSS MD PhD

    Peter: Petit a petit, l’oiseau fait son nid. I just posted here a long commentary about Abi but the system gobbled it....

  • Dr. KSS MD PhD

    I don't know a good way to get early information though escalating buying 2-3 days in advance is often a tip-off. The id...

  • Avatar

    Long $AAVXF I listened to the presentation and just a few thoughts: -Abivax collaborates and shares labs with CNRS whi...

  • Avatar

    Abivax -- Not a ton of info, but it was just released today. http://www.abivax.com/images/pdf/PR_ABIVAX_DDR_11052017.pd...

  • Avatar

    I had a backup recording going on my iPhone and sadly didn't manage to collect the entire unrecorded part but did get ab...

  • Avatar

    Excellent question. And what other companies are actively trying to eradicate HIV? long $aavxf...

  • Avatar

    Without the numbers and such a small sample it's hard to say. Note "no response" in this context just means it didn't me...

  • Avatar

    Genef: If you have a Canadian bank account, you should be able to open an a/c with IB. They trade worldwide stocks for a...

  • Avatar

    I'm a new gumshoe member and have been fascinated by Dr. KSS and this community. I am also a physician (addiction psychi...

  • Avatar

    Thank you. I think the pipeline is much more valuable than ABX-464 HIV. The smart strategy for AbiVax would be to spi...

  • Dr. KSS MD PhD

    Hi Miceal: Agree it's a VERY formidable roster of people. The CEO is someone I admire, and they have plum HIV experts on...

  • Avatar

    Good Morning Dr. KSS ! A big THANK YOU ! Amazing ! What do you see as significance of press release? What I find am...

  • Avatar

    "In the ABX464-004 trial, 30 HIV patients were enrolled in Spain, Belgium and France. Patients were enrolled in a 3:1 ra...

  • Avatar

    First ever evidence of treatment-induced reduction in HIV reservoirs: ABX464, ABIVAX’ lead drug candidate, impacted HI...

  • Avatar

    Long $AAVXF So I just checked the Abivax.com website and there is this on the home page: 2 May 2017 Réduction, pour...

  • Dr. KSS MD PhD

    Hi ppkaul: Pro140 is a useful agent against HIV, as is the TaiMed monoclonal antibody being developed by that firm in Ta...

  • Dr. KSS MD PhD

    Interesting points, but I find myself politely disagreeing with both. First, prion-like events, changes in structure lea...

  • Avatar

    Dr. KSS—A contact to talk to about AbiVax: Dr. Ian McGowan-- Professor of Medicine in the Division of Gastroenterol...

  • SoGiAm

    AKAO long - Fears over new superbug in NZ appx 12 minute audio http://www.radionz.co.nz/national/programmes/thepan...

  • Avatar

    Great article, Dr. KSS -- I've been happily waiting for this one. I don't know if it was your intention or not -- but...

  • Avatar

    Interesting company, thanks. How would you compare their drug versus Pro140 being tested by Cytodyn (CYDY)? I gather Pro...

  • Avatar

    Thank you. I had a feeling this was the company you teased. :). Out of curiosity, how do yo feel about Cydy who is als...

  • Avatar

    $ABVX.PA/$AAVXF(OTC): For HIV ABX-464 the MoA is just similar to many other HIV drug, it prevents viral replication. B...

  • Avatar

    @Cw $No Ticker, if I remember rightly from the most recent conference call, I think the Doc said that his mysterious 12t...

  • Avatar

    $CYDY long Interesting question, because my understanding of Orphan Drug Designation is really that you should know if ...

  • Avatar

    No Position $CYDY I assume that the failure to get Orphan Drug Designation from the FDA is bad. However, the reason t...

  • SoGiAm

    $CYDY small long - Potential for CytoDyn’s PRO 140 for Treating HIV Patients Deemed Too Broad for Orphan Drug Designat...

  • Avatar

    Thanks for posting, Ben. Long $CYDY. But... Why would an HIV and other disease company hire a Director from Resurgens, ...

  • Avatar

    Thanks for posting, Ben. It looks like they have missed their assumed deadline, unless they publish results tomorrow. Ph...

  • SoGiAm

    $CYDY long - Investor presentation: First self-administered antibody therapy for HIV in late-stage clinical trials htt...

  • Avatar

    $cydy Long Doc, a week or so back you had mentioned your dampening ardor for $CYDY, basically along the lines that cert...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch